Mar 6, 2020
Even as both medical and adult use cannabis legalization has continued across the United States, growers and retailers have faced a number of challenges, like how to standardize and regulate a product that isn’t always easy to measure. In the CBD space in particular, it’s easy to end up with “hot” product where THC levels are too high to be legal.
Rick Kimball is tackling this issue head-on. He’s the president of Rymedi - a tech company building a trusted, secure, and compliant track and trace platform designed to meet the specialized regulatory needs of the healthcare industry. Before founding Rymedi, he spent over 30 years as an investment banker and venture capitalist at firms including Goldman Sachs, Morgan Stanley, and Millennium Technology Partners.
Today, Rick joins the podcast to talk us through the issues facing the CBD industry, how Rymedi works to help everyone along the supply chain, and the emerging innovations in this field that have a lot of people excited right now.
KEY TAKEAWAYS
SHOW NOTES
For complete show notes, including transcripts, takeaways, and links to all the resources mentioned, visit SoHoExp.com/10
To learn more about the podcast and get access to all episodes, visit: SoHoExp.com/GreenRepeal